Mark Lebwohl, MD

This Q&A interview highlights the broader implications of the phase 3b TOGETHER-PsO trial for ixekizumab and tirzepatide in managing psoriatic disease.

This interview highlights recent phase 3b data from the TOGETHER-PsO trial on ixekizumab and tirzepatide for psoriasis and obesity or overweight.

Learn how to personalize systemic psoriasis care, weigh comorbidities, and aim for rapid clearance to reduce heart and joint risks.

Learn how dermatologists tailor psoriasis treatment—topicals, phototherapy, pills or biologics—using shared decisions, severity and comorbidities.

Explore how cutting inflammation in psoriasis may lower heart risks, and why new oral TYK2 inhibitors could broaden treatment beyond injections.

Derm experts compare TYK2 pills with biologics for psoriasis—safety, speed, infections, and when combination therapy helps stubborn skin and joints.

Experts explain how deucravacitinib eases psoriasis itch fast, boosts quality of life, and why TB testing and boxed warnings matter.

New oral psoriasis therapy delivers biologic-level skin clearance in tough patients, with PASI 100 rising to 42% by week 24.

Psoriasis care shifts beyond skin: treat-to-target goals, heart risk reduction, and new oral TYK2 pills with strong safety data.

Discover how oral TYK2 inhibitors deliver targeted psoriasis control with strong safety data and biologic-like clearance, including insights on deucravacitinib and zasocitinib.

Expert dermatologists urge aggressive psoriasis control to prevent heart and joint risks, highlight unmet needs, and preview TYK2 inhibitors as a safer oral option.

Explore how TYK2 inhibitors reshape psoriasis care, as experts weigh comorbidities, infection screening, and treat-to-target goals to overcome real-world treatment hurdles.

At AAAAI 2026, Lebwohl discussed REMIX trial data showing oral remibrutinib reduced CSU symptoms within 12 hours and improved disease control.

HCPLive speaks with Mark Lebwohl, MD, about recent data on those with psoriasis and obesity or overweight treated with ixekizumab (Taltz) and tirzepatide (Zepbound).

During this EADV interview, Lebwohl speaks to some of the most recent developments in the psoriasis research space.

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors represent a promising new therapeutic class for chronic spontaneous urticaria (CSU) by offering rapid symptom control through targeted inhibition of both mast cell and B cell pathways, with newer agents like remibrutinib showing high selectivity, favorable safety, and robust efficacy in clinical trials that could position them as an important oral therapy option between antihistamines and biologics.

Panelists discuss how future research should focus on identifying biomarkers for patient selection, understanding long-term safety profiles, exploring combination therapy approaches, and determining optimal treatment duration with Bruton tyrosine kinase (BTK) inhibitors in chronic spontaneous urticaria (CSU).

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors could transform chronic spontaneous urticaria (CSU) treatment by offering a targeted oral therapy option that works rapidly across both autoallergic and autoimmune subtypes, potentially providing an effective alternative before escalating to biologics or immunosuppressants.

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors appear to offer faster symptom relief and higher complete response rates compared with current chronic spontaneous urticaria (CSU) treatments like antihistamines and omalizumab while potentially requiring less frequent dosing and showing favorable safety profiles.

Panelists discuss how rilzabrutinib shows promise in phase 2 trials with rapid improvements in disease activity scores (UAS7 and ISS7) starting from week 1 and a favorable safety profile, setting expectations for the upcoming phase 3 studies to confirm these initial findings.

Panelists discuss how chronic spontaneous urticaria (CSU) significantly impacts patients’ quality of life through persistent itching, unpredictable flares, sleep disruption, emotional distress, and daily activity limitations, underscoring the need for effective disease control.

Panelists discuss how remibrutinib demonstrated rapid and sustained efficacy in the REMIX-1 and -2 trials through significant improvements in disease activity scores (UAS7, ISS7, HSS7) starting at week 1 and maintained through 52 weeks, with nearly half of patients achieving complete symptom resolution (UAS7 = 0) by week 52, while maintaining a favorable safety profile throughout the study period.

Panelists discuss how pharmacological Bruton tyrosine kinase (BTK) inhibition with agents like remibrutinib appears safer than genetic BTK deficiency (X-linked agammaglobulinemia [XLA]), as clinical studies show the drug doesn't significantly impact immunoglobulin levels or infection rates in patients with chronic spontaneous urticaria (CSU), unlike the severe immunodeficiency seen in XLA.

Panelists discuss how newer Bruton tyrosine kinase (BTK) inhibitors being developed for chronic spontaneous urticaria (CSU), particularly remibrutinib (in phase 3 trials) and rilzabrutinib (in phase 2), are designed to be more selective than earlier oncology-focused BTK inhibitors, potentially reducing off-target effects like bleeding, cardiovascular complications, and GI issues.

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors offer a novel upstream approach, in contrast to current treatments that work downstream by either blocking released mediators (antihistamines), neutralizing circulating IgE (omalizumab), or broadly suppressing immune responses (immunosuppressants).

Panelists discuss how Bruton tyrosine kinase (BTK) inhibition could effectively treat both autoallergic and autoimmune chronic spontaneous urticaria (CSU).

Panelists discuss how chronic spontaneous urticaria (CSU) treatment targets multiple pathways through antihistamines, anti-IgE therapy, and BTK inhibitors, with BTK emerging as a key target.

Panelists discuss how chronic spontaneous urticaria develops through 2 distinct pathways: autoallergic CSU involving IgE-mediated mast cell activation (type I hypersensitivity) and autoimmune CSU where IgG autoantibodies target FcεRI receptors or IgE itself (type IIb hypersensitivity), both ultimately leading to mast cell degranulation and wheal formation.

Experts conclude the series discussing how to approach switching psoriasis treatments.

Experts discuss package warnings associated with bimekizumab and how they inform patients of them.